AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
ANAB Stock Chart & Stats
$67.51
-$0.23(-1.55%)
At close: 4:00 PM EST
$67.51
-$0.23(-1.55%)
Day’s Range― - ―
52-Week Range$17.11 - $73.30
Previous CloseN/A
Volume154.73K
Average Volume (3M)627.22K
Market Cap
$2.03B
Enterprise Value$3.04B
Total Cash (Recent Filing)$311.64M
Total Debt (Recent Filing)$290.64M
Price to Earnings (P/E)4.5
Beta0.81
Next Earnings
May 07, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,100,903
10 Day Avg. Volume537,791
30 Day Avg. Volume627,217
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue12.96
Enterprise Value/Gross Profit13.09
Enterprise Value/Ebitda45.55
Forecast
1Y Price Target
$78.27Price Target Upside15.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.69
Revenue Forecast (FY)$105.03M
Bulls Say, Bears Say
Bulls Say
Clinical Development CatalystsUpcoming topline phase 1b results and multiple near-term program readouts for the lead antibody could drive stock gains if they show meaningful clinical benefit in celiac disease and related indications.
Corporate RestructuringPlanned separation into a royalty company and a biopharma company could unlock value by letting the royalty arm focus on steady income while the biopharma arm advances drug development.
Differentiated Therapeutic MechanismLead program's dual-targeting approach addresses immune pathways not reached by single-target therapies, potentially improving efficacy and commercial prospects if clinical signals hold up.
Bears Say
Class-level Clinical RiskDiscontinuation of a peer's similar program highlights class-level safety or efficacy concerns and raises uncertainty about regulatory and commercial prospects for comparable therapies.
Legal Risk To Royalty RevenueAn ongoing legal dispute with a partner creates meaningful downside risk to expected royalty revenues while breach claims remain unresolved.
Tax Implications For ShareholdersDistribution of new shares as a taxable transaction may create a tax burden for shareholders and could reduce demand for the spun-off equity.
AnaptysBio News
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $17.11 and its highest was $73.30 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $2.03B.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is May 07, 2026 which is today.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Mar 03, 2026. The company reported $1.053 earnings per share for the quarter, beating the consensus estimate of $0.575 by $0.478.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -0.64.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 29,100,903 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of $1.053 in its last earnings report, beating expectations of $0.575. Following the earnings report the stock price went up 14.614%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.27 (15.94% Upside)
$78.27 (15.94% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
228.51%
12-Months-Change
Fundamentals
Return on Equity
1813.84%
Trailing 12-Months
Asset Growth
-24.69%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Stock 12 Month Forecast
Average Price Target
$78.27
▲(15.94% Upside)
Technical Analysis
Meiragtx Holdings
―
Keros Therapeutics
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Terns Pharmaceuticals
―
Ownership Overview
2.26% Insiders
11.47% Mutual Funds
0.91% Other Institutional Investors
73.82% Public Companies and
Individual Investors